IxC 162
Latest Information Update: 03 Dec 2003
At a glance
- Originator Ixion Biotechnology
- Class Enzymes
- Mechanism of Action Oxalate inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Cystic fibrosis; Inflammatory bowel diseases; Kidney disorders
Most Recent Events
- 03 Dec 2003 No development reported - Preclinical for Crohn's disease in USA (unspecified route)
- 03 Dec 2003 No development reported - Preclinical for Cystic fibrosis in USA (unspecified route)
- 03 Dec 2003 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)